Reviewed by Michael Gill, B. Sc.
25 Neuroendocrine Tumor Clinical Trials Near Me
Top Hospitals for Neuroendocrine Tumor Clinical Trials
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
7Active Trials
20All Time Trials for Neuroendocrine Tumor
2008First Neuroendocrine Tumor Trial
Image of Moffitt Cancer Center in Florida.
Moffitt Cancer Center
Tampa
5Active Trials
16All Time Trials for Neuroendocrine Tumor
2007First Neuroendocrine Tumor Trial
Top Cities for Neuroendocrine Tumor Clinical Trials
Neuroendocrine Tumor Clinical Trials by Phase of Trial
Phase < 1 Neuroendocrine Tumor Clinical Trials
5Active Neuroendocrine Tumor Clinical Trials
5Number of Unique Treatments
5Number of Active Locations
Neuroendocrine Tumor Clinical Trials by Age Group
18+ Neuroendocrine Tumor Clinical Trials
57Active Neuroendocrine Tumor Clinical Trials
Most Recent Neuroendocrine Tumor Clinical Trials
Top Treatments for Neuroendocrine Tumor Clinical Trials
Treatment Name
Active Neuroendocrine Tumor Clinical Trials
All Time Trials for Neuroendocrine Tumor
First Recorded Neuroendocrine Tumor Trial
177Lu-DOTATOC
2
5
2019
Pembrolizumab
2
7
2015
Cabozantinib
2
7
2012
Capecitabine
2
9
2005
[18F]FETrp PET radiotracer
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Neuroendocrine Tumor
Treatment
Year
Sponsor
XmAb18087
2018
Xencor, Inc.
Somatuline Depot
2017
Duke University

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 29th, 2021

Last Reviewed: November 23rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102. https://pubmed.ncbi.nlm.nih.gov/248124032 Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102. https://pubmed.ncbi.nlm.nih.gov/248124033 Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. https://pubmed.ncbi.nlm.nih.gov/250146874 Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24. https://pubmed.ncbi.nlm.nih.gov/197040575 Levy PL, Gros A. Fast track to personalized TCR T cell therapies. Cancer Cell. 2022 May 9;40(5):447-449. doi: 10.1016/j.ccell.2022.04.013. Epub 2022 May 9. https://pubmed.ncbi.nlm.nih.gov/355374086 Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun;19(6):747-52. doi: 10.1038/nm.3161. Epub 2013 May 5. https://pubmed.ncbi.nlm.nih.gov/236445167 Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42. doi: 10.1210/jc.2014-1498. https://pubmed.ncbi.nlm.nih.gov/248931358 Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290. https://pubmed.ncbi.nlm.nih.gov/213062389 Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501-13. doi: 10.1056/NEJMoa1003825. Erratum in: N Engl J Med. 2011 Mar 17;364(11):1082. https://pubmed.ncbi.nlm.nih.gov/2130623710 Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, Schrope B, Allendorf J, Lee JA, Sherman WH, Chabot JA. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013 Mar;71(3):663-70. doi: 10.1007/s00280-012-2055-z. Epub 2013 Jan 31. https://pubmed.ncbi.nlm.nih.gov/23370660